APA

Neri B., Doni L., Fulignati C., Gemelli M. T., Turrini M., Di Cello V., Dominici A., Mottola A., Raugei A., Ponchietti R. & Cini G. (20030220). Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II. : Anticancer research.

Chicago

Neri B, Doni L, Fulignati C, Gemelli M T, Turrini M, Di Cello V, Dominici A, Mottola A, Raugei A, Ponchietti R and Cini G. 20030220. Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II. : Anticancer research.

Harvard

Neri B., Doni L., Fulignati C., Gemelli M. T., Turrini M., Di Cello V., Dominici A., Mottola A., Raugei A., Ponchietti R. and Cini G. (20030220). Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II. : Anticancer research.

MLA

Neri B, Doni L, Fulignati C, Gemelli M T, Turrini M, Di Cello V, Dominici A, Mottola A, Raugei A, Ponchietti R and Cini G. Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II. : Anticancer research. 20030220.